Finance Resource

Specialty+biopharmaceutical+company Jobs | Indeed.com. Job search for 48 Specialty+biopharmaceutical+company Jobs at indeed.com. one search. . global specialty biopharmaceutical company marketing.　->

Shire presents study findings on its ADHD treatments at .. Shire plc, the global specialty biopharmaceutical company, announced today that . become the leading specialty biopharmaceutical company that focuses on meeting .　->

CSL Limited. CSL Limited is a global, specialty biopharmaceutical company that researches, develops, manufactures and markets products to treat and prevent serious human medical .　->

Shire Reports Positive Results From First of Three Phase III .. . SHPGY), the global specialty biopharmaceutical company, today reported positive . become the leading specialty biopharmaceutical company that focuses on meeting .　->

Shire to Enter European ADHD Market With the Acquisition of .. Shire plc , the global specialty biopharmaceutical company, announces that it has signed an agreement with UCB to acquire the worldwide rights to EQUASYM(R) IR　->

SciClone Pharmaceuticals Reports Third Quarter Results. . (Nasdaq: SCLN), a global specialty biopharmaceutical company, announced that it . is a global specialty biopharmaceutical company that develops and .　->

PharmaLive: Shire and Sandoz Settle all Pending Litigation .. . FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty . become the leading specialty biopharmaceutical company that focuses on meeting .　->

Shire and Sandoz Settle all Pending Litigation Concerning .. . SHPGY), the global specialty biopharmaceutical company, announces that it has settled all . leading specialty biopharmaceutical company that focuses .　->

Shire and Sandoz Settle all Pending Litigation Concerning .. PHILADELPHIA, October 13 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has settled .　->

Shire Reports Tolerability And Clinical Effects Results Of .. Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings at a major medical meeting from a Phase IIIb study of the .　->